Amoxicillin + Clavulanate

Co-amoxiclav combines two ingredients with complementary roles. The first, amoxicillin, is an aminopenicillin that kills bacteria by blocking the construction of their cell walls. The second, clavulanic acid, has little antibacterial power of its own but acts as a decoy that disables beta-lactamase, the enzyme many resistant bacteria produce to break apart penicillins ^[1]. By protecting amoxicillin from this enzyme, clavulanic acid restores and broadens the antibiotic's reach ^[1].

The pairing addresses one of amoxicillin's main weaknesses. On its own, amoxicillin is inactivated by beta-lactamase-producing organisms such as many strains of Staphylococcus aureus, Haemophilus influenzae, and gut bacteria. Adding clavulanic acid, which binds these enzymes irreversibly, allows amoxicillin to reach its target and act on such strains, extending coverage to include many resistant respiratory bacteria and anaerobes ^[1].

Because of this wider spectrum, co-amoxiclav is chosen when resistant bacteria are likely or when plain amoxicillin has failed. It is recommended as a first-line treatment for acute bacterial sinus infection ^[2], and it is used for ear and respiratory infections, skin and soft-tissue infections, and urinary infections. It is a standard choice for the bite wounds of animals and humans, whose bacteria are often resistant to simpler penicillins ^[2].

The addition of clavulanic acid comes at a cost in tolerability. Co-amoxiclav causes more diarrhea and stomach upset than amoxicillin taken alone, an effect largely attributed to the clavulanate component. More importantly, it is one of the more common causes of drug-induced liver injury, typically a cholestatic hepatitis in which bile flow is impaired; the jaundice can appear days to weeks after the course is finished and may be prolonged ^[3]. This reaction is uncommon and usually resolves, and it is more likely in older people, in men, and with repeated courses ^[3]. Research has linked susceptibility to particular immune-system genes, pointing to an allergic or immune basis for the liver injury ^[4].

Co-amoxiclav is made in several fixed ratios of amoxicillin to clavulanic acid and is available as tablets, chewable tablets, oral suspensions, and, in some countries, an intravenous form ^[1]. It was introduced in the 1980s, is a prescription-only medicine, and is available as a generic; it appears on lists of essential medicines because of its usefulness against resistant everyday infections.

This is a prescription antibiotic. The most common effects are diarrhea (more than with amoxicillin alone, because of the clavulanate), nausea, rash and yeast infections, and it can cause C. difficile colitis. Its more distinctive risk is a reversible cholestatic liver injury or jaundice, which is more likely with longer or repeated courses and in older patients. People with a true penicillin allergy should not take it. It can occasionally raise the effect of warfarin, and taking it with food reduces stomach upset. Doses are reduced in significant kidney impairment.

The combination arose from Beecham's discovery of clavulanic acid, a compound produced by the soil bacterium Streptomyces clavuligerus that could disable the beta-lactamase enzymes many bacteria use to destroy penicillins. Pairing this beta-lactamase inhibitor with amoxicillin restored the antibiotic's power against otherwise resistant organisms, and the fixed combination was launched as Augmentin in the early 1980s. It rapidly became a widely used broad-spectrum oral antibiotic for sinus, respiratory, dental, and bite infections. Its history also carries a cautionary thread; the clavulanate component is linked to the combination's greater tendency to cause digestive upset and, uncommonly, immune-mediated liver injury.

Co-amoxiclav, best known as Augmentin, is respected as a reliable step up from plain amoxicillin, extending coverage to many beta-lactamase-producing bacteria while keeping the familiar convenience of an oral penicillin. Prescribers reach for it in sinusitis, more stubborn respiratory infections, and human or animal bites, where its broader reach is genuinely useful. Its clever suicide-inhibitor design, in which clavulanic acid sacrifices itself to protect the antibiotic, is often cited as an elegant piece of pharmacology. Honesty requires noting its trade-offs; it causes more diarrhea than amoxicillin alone and is one of the more common causes of drug-induced liver injury, so it is best reserved for situations that truly need it.